NCT00031642 2023-12-27
Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation
University of Nebraska
Phase 1/2 Completed
Clinical Trials
10 trialsNCT00562978 2021-06-18
Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients
City of Hope Medical Center
Phase 1/2 Completed
NCT00372905 2019-09-04
Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
Northwestern University
Phase 1/2 Terminated
NCT00089284 2019-08-14
Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
Northwestern University
Phase 1/2 Terminated
NCT00012298 2018-08-09
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00438880 2016-02-04
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT01538472 2014-09-11
Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00064246 2013-01-25
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00397800 2012-08-28
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma
Technical University of Munich
Phase 1/2 Unknown
NCT00807196 2008-12-11
Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma
Maisonneuve-Rosemont Hospital
Phase 1/2 Unknown